Skip to main content
GIPResearch.com · Patent and Technology Research

Dipharma Francis S.R.L Received a Patent for Pteridine Derivatives

Dipharma is a European manufacturer of Active Pharmaceutical Ingredients that has been developing innovative and proprietary processes since 1949.

Save or follow this source
These actions open third-party AI services. Saving, citation, and future recall are not guaranteed.
Conceptual GIPResearch illustration for Dipharma Francis S.R.L Received a Patent for Pteridine Derivatives
Research and original publication material

Dipharma Francis S.R.L Received a Patent for Pteridine Derivatives — research background

Research context: This article preserves existing publication material for continuity. Technical, commercial and legal references should be checked against current primary sources before making decisions.

Dipharma is a European manufacturer of Active Pharmaceutical Ingredients that has been developing innovative and proprietary processes since 1949. They support their customers worldwide with a strong and well resourced R&D team, three cGMP facilities in Europe, and offer world-renowned expertise in handling hazardous chemical processes. Their customers can benefit from their broad portfolio of generic Active Pharmaceutical Ingredients and a wide range of advanced technologies available for custom synthesis. Dipharma Francis S.R.L filed patent application numbered 3957/KOLNP/2012 that is titled PROCESS FOR THE PREPARATION OF PTERIDINE DERIVATIVES.  This patent application has been granted as Patent Number 312917.  The invention covers Chemical compounds. The application discloses a process for the preparation of 5-deoxy-L-arabinose of formula (VI); comprising the conversion of a compound of formula (XII); wherein n is 0, 1 or 2; which can be used as intermediate for the synthesis of sapropterin. During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act, wherein the examiner stated that the Claim(s) (1-12) are statutorily non-patentable and It is the mere discovery of known process. without any advantageous over the process is shown in the prior art. As a response, the applicant revised the claims and are claimed to be new, with improved yields. Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter. Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech). Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.

Discuss a research question related to Dipharma Francis S.R.L Received a Patent for

Describe your objective and the evidence you need. The suitability and scope of any research engagement will be confirmed individually.

Discuss a research question

Source and context: Original GIPResearch.com publication dated 2019-08-28. Existing text is retained for historical continuity. Verify time-sensitive matters using official records.

None

Featured Work & Insights